Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px
Document › Details

DNA Script. (3/23/21). "Press Release: DNA Script Names Philippe Lyko as Chief Financial Officer". San Francisco, CA & Paris.

Region Region United States (USA)
Organisation Organisation DNA Script S.A.S.
  Group DNA Script (Group)
Products Product Syntax™ EDS system (enzymatic DNA printer)
  Product 2 DNA synthesis
Persons Person Lyko, Phillipe (DNA Script 202103– CFO before Flexport + Helix + Illumina + GE Healthcare)
  Person 2 Ybert, Thomas (DNA Script 201709 CEO + Co-Founder)

Former Illumina and Helix finance executive brings deep experience with emerging and established life science companies

DNA Script, a leader in revolutionizing DNA synthesis on demand to accelerate scientific breakthroughs, has appointed Philippe Lyko as its new Chief Financial Officer. Lyko brings over 20 years of diverse operational finance expertise in diverse industries, geographies, business cycles and profit drivers. Lyko’s prior demonstrated experience, particularly at other dynamic, US-based life science and healthcare companies, will be instrumental as DNA Script accelerates the commercialization of its SYNTAX™ platform.

Lyko joins the company from Flexport, a $1Bn+ digital freight forwarding company where he acted as Interim CFO for the past two years. He was critical to scaling the finance operations during a period of rapid growth for the company. Lyko spent three years leading operational finance as the Vice President of Finance at Helix, a leader in population genomics. He also spent seven years in a hyper-growth and business transformation environment as the Senior Finance Director at Illumina. Lyko’s acumen in growing emerging businesses and scaling operations allowed him to build the financial organizations during critical growth periods. Lyko began his career in life sciences and healthcare at General Electric, serving 10 years in various international divisions.

“Philippe will play a transformative role at DNA Script as we launch the commercialization of the SYNTAX platform and progress toward our goal of revolutionizing DNA synthesis on demand,” said Thomas Ybert, co-founder and CEO of DNA Script. “With his experience in leading the financial operations of several emerging and established companies, he will play a key role in positioning the company for the future.”

About DNA Script

Founded in 2014, DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science. The company is pioneering an alternative to traditional DNA synthesis called enzymatic DNA synthesis, or EDS, making this technology accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX™ System. By putting DNA synthesis back in the lab, DNA Script is transforming life science research through innovative technology that gives researchers full control and unprecedented autonomy.

Press contact in the US

Valerie Enes

Press contact in Europe

Caroline Carmagnol
+33 6 64 18 99 59

DNA Script Contact

Record changed: 2021-07-30


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for DNA Script (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC E Hand 650x300px

» top